Name in SEC filings: Kura Oncology, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| darlifarnib + cabozantinib | /data readout | Phase 1 | second half of 2026 | 10-Q · |
| ziftomenib + gilteritinib | Topline/data readout | Stage not stated | second half of 2026 | 10-Q · |
| ziftomenib + quizartinib + 7+3 | Topline/data readout | Stage not stated | second half of 2026 | 10-Q · |
| ziftomenib + venetoclax + azacitidine | Topline/data readout | Phase 1 | 2026 | 8-K · |
| darlifarnib + cabozantinib | Topline/data readout | Stage not stated | second half of 2027 | 10-Q · |
| ziftomenib | Topline/data readout | Stage not stated | 2028 | 10-Q · |
Source: ORION, orionbiotechai.com/company/KURA, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/KURA
darlifarnib + cabozantinib · Topline/data readout · second half of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1a”
Public float: $496,100,000 · as of · SEC filing
updated Phase 1a dose-escalation data from the combination of darlifarnib and cabozantinib in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Not stated
Public float: $496,100,000 · as of · SEC filing
anticipate presenting preliminary data in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Not stated
Public float: $496,100,000 · as of · SEC filing
anticipate presenting preliminary data in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2H 2026
Stage: Phase 1SEC filing · “Phase 1b”
Public float: $496,100,000 · as of · SEC filing
Updated long-term KOMET-007 Phase 1b data evaluating ziftomenib with venetoclax and azacitidine in newly diagnosed, intensive chemotherapy-ineligible NPM1 -m AML patients, including durability, survival, and MRD outcomes – 2H 2026
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2027
Stage: Not stated
Public float: $496,100,000 · as of · SEC filing
initial clinical data in the second half of 2027
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Topline/data readout2028
Stage: Not stated
Public float: $496,100,000 · as of · SEC filing
topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2028-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| darlifarnib + cabozantinibClinical results | second half of 2027“initial clinical data in the second half of 2027” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| ziftomenibClinical results | 2028“topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| ziftomenib + gilteritinibClinical results | second half of 2026“anticipate presenting preliminary data in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ziftomenib + quizartinib + 7+3Clinical results | second half of 2026“anticipate presenting preliminary data in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ziftomenib + venetoclax + azacitidineClinical results | 2H 2026“Updated long-term KOMET-007 Phase 1b data evaluating ziftomenib with venetoclax and azacitidine in newly diagnosed, intensive chemotherapy-ineligible NPM1 -m AML patients, including durability, survival, and MRD outcomes – 2H 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| darlifarnib + cabozantinibClinical results | second half of 2026“updated Phase 1a dose-escalation data from the combination of darlifarnib and cabozantinib in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ziftomenibClinical results | 2028“topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| ziftomenibClinical results | 2028“topline results from KOMET-017, anticipated in 2028” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| darlifarnib + cabozantinibClinical results | second half of 2026“updated Phase 1a dose-escalation data from the combination in the second half of 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| ziftomenibClinical results | 2028“topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| ziftomenibClinical results | 2028“topline results from KOMET-017, anticipated in 2028” Filed · 10-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| ziftomenib + gilteritinibClinical results | 2026“data from the KOMET-008 cohort evaluating ziftomenib in combination with gilteritinib in patients with relapsed or refractory NPM1-mutated AML in 2026” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for KURA. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See KURA in the calendar · Review labels and methodology